4/2
02:09 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
4/1
10:39 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Scotiabank from $24.00 to $20.00. They now have a "sector outperform" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Scotiabank from $24.00 to $20.00. They now have a "sector outperform" rating on the stock.
3/26
01:32 pm
mygn
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/25
11:05 pm
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/17
07:19 am
mygn
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
Low
Report
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
3/13
02:07 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/12
01:38 pm
mygn
Why Are Myriad Genetics (MYGN) Shares Soaring Today [Yahoo! Finance]
Low
Report
Why Are Myriad Genetics (MYGN) Shares Soaring Today [Yahoo! Finance]
3/12
07:37 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $12.50 price target on the stock, up previously from $11.50.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $12.50 price target on the stock, up previously from $11.50.
3/11
06:28 am
mygn
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]
Medium
Report
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]
3/4
11:59 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $14.00 to $11.50. They now have a "neutral" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $14.00 to $11.50. They now have a "neutral" rating on the stock.
3/3
08:31 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $13.00 to $11.00. They now have an "underperform" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $13.00 to $11.00. They now have an "underperform" rating on the stock.
3/1
02:03 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/27
05:49 pm
mygn
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools [Yahoo! Finance]
Low
Report
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools [Yahoo! Finance]
2/27
04:15 pm
mygn
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Low
Report
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
2/25
02:24 pm
mygn
Why Myriad Genetics (MYGN) Shares Are Plunging Today [Yahoo! Finance]
Low
Report
Why Myriad Genetics (MYGN) Shares Are Plunging Today [Yahoo! Finance]
2/25
12:35 pm
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $19.00 price target on the stock, down previously from $27.00.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $19.00 price target on the stock, down previously from $27.00.
2/25
10:32 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at UBS Group AG from $18.00 to $16.00. They now have a "neutral" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at UBS Group AG from $18.00 to $16.00. They now have a "neutral" rating on the stock.
2/24
06:06 pm
mygn
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth [Yahoo! Finance]
High
Report
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth [Yahoo! Finance]
2/24
06:06 pm
mygn
Myriad Genetics Announces Senior Leadership Transition [Yahoo! Finance]
High
Report
Myriad Genetics Announces Senior Leadership Transition [Yahoo! Finance]
2/24
05:03 pm
mygn
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops [Yahoo! Finance]
Medium
Report
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops [Yahoo! Finance]
2/24
04:05 pm
mygn
Myriad Genetics Announces Senior Leadership Transition
High
Report
Myriad Genetics Announces Senior Leadership Transition
2/24
04:05 pm
mygn
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
High
Report
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
2/24
09:04 am
mygn
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio [Yahoo! Finance]
Low
Report
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio [Yahoo! Finance]
2/24
08:30 am
mygn
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
Low
Report
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
2/23
12:52 pm
mygn
What To Expect From Myriad Genetics's (MYGN) Q4 Earnings [Yahoo! Finance]
Medium
Report
What To Expect From Myriad Genetics's (MYGN) Q4 Earnings [Yahoo! Finance]